Tekla Life Sciences Investors (HQL) — Financial statements
Income statement, balance sheet, and cash flow for Tekla Life Sciences Investors — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 86↓0.3% | 87↑120.1% | 39↑23.6% | 32↓29.2% | 45 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 5↓5.5% | 6↓8.7% | 6 | |
| Gross Profit | 86↓0.3% | 87↑374.2% | 18↓30.5% | 26↓32.4% | 39 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00↑100.0% | -0.00 | 0.00 | |
| General & Administrative Expenses | 0.74↓44.2% | 1↑47.5% | 0.90↓16.1% | 1↑27.6% | 0.84 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 0.74↓44.2% | 1↑47.5% | 0.90↓16.1% | 1↑27.6% | 0.84 | |
| Other Expenses | 0.05↓14.6% | 0.06↓78.9% | 0.27↓2.8% | 0.28↓12.0% | 0.31 | |
| Operating Expenses | 0.79↓43.0% | 1↑18.6% | 1↓13.4% | 1↑16.8% | 1 | |
| Total Costs & Expenses | 0.79↓43.0% | 1↓91.8% | 17↓87.5% | 136↑799.3% | -20 | |
| Operating Results | ||||||
| Operating Income | 86↑0.3% | 85↑1726.5% | -5↑95.0% | -105↓262.1% | 65 | |
| Depreciation & Amortization | 0.00↓100.0% | 2↓93.0% | 28↑823.0% | 3↓27.8% | 4 | |
| EBITDA | 86↓1.9% | 87↑74.6% | 50↑149.2% | -102↓248.0% | 69 | |
| EBIT | 86↑0.3% | 85↑281.6% | 22↑121.4% | -105↓262.1% | 65 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.35↓66.5% | 1↑410.2% | 0.20↑308.1% | 0.05 | 0.00 | |
| Interest Income | 0.35↓66.5% | 1↑410.2% | 0.20↑308.1% | 0.05 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.00↓100.0% | 87↑216.0% | 28↑1141658.2% | 0.00↑130.9% | -0.01 | |
| Income Before Tax | 86↑0.3% | 85↑281.6% | 22↑121.4% | -105↓262.1% | 65 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 86↑0.3% | 85↑281.6% | 22↑121.4% | -105↓262.1% | 65 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 86↑0.3% | 85↑281.6% | 22↑121.4% | -105↓262.1% | 65 | |
| Bottom-Line Net Income | 86↑0.3% | 85↑281.6% | 22↑121.4% | -105↓262.1% | 65 | |
| EPS (Basic) | 2.96↓2.6% | 3.04↑284.8% | 0.79↑119.4% | -4.07↓253.0% | 2.66 | |
| EPS (Diluted) | 2.96↓2.6% | 3.04↑284.8% | 0.79↑119.4% | -4.07↓253.0% | 2.66 | |
| Weighted Average Shares | 29↑2.9% | 28↓0.8% | 28↑10.2% | 26↑5.9% | 24 | |
| Weighted Average Diluted Shares | 29↑2.9% | 28↓0.8% | 28↑10.2% | 26↑5.9% | 24 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.